Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

B of A Securities Downgrades Greif to Underperform, Lowers Price Target to $67

B of A Securities analyst George Staphos downgrades Greif (NYSE:GEF) from Buy to Underperform and lowers the price target from $80 to $67.
byBenzinga Newsdesk
October 13, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

B of A Securities analyst George Staphos downgrades Greif (NYSE:GEF) from Buy to Underperform and lowers the price target from $80 to $67.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial

By Lara Goldstein
April 17, 1:26 PM
Psychedelics biopharma company Mind Medicine Inc.’s (NASDAQ: MNMD) shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive Disorder (MDD) on Friday — just a couple of days before the 80th anniversary of the discov

MNMD